Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,270 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Aiko N, Shimokawa T, Miyazaki K, Misumi Y, Agemi Y, Ishii M, Nakamura Y, Yamanaka T, Okamoto H. Aiko N, et al. Among authors: nakamura y. BMC Cancer. 2018 Oct 22;18(1):1012. doi: 10.1186/s12885-018-4911-7. BMC Cancer. 2018. PMID: 30348116 Free PMC article.
A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630.
Taniguchi Y, Shimokawa T, Takiguchi Y, Misumi T, Nakamura Y, Kawashima Y, Furuya N, Shiraishi Y, Harada T, Tanaka H, Miura S, Uchiyama A, Nakahara Y, Tokito T, Naoki K, Bessho A, Goto Y, Seike M, Okamoto H. Taniguchi Y, et al. Among authors: nakamura y. Clin Cancer Res. 2022 Oct 14;28(20):4402-4409. doi: 10.1158/1078-0432.CCR-22-1687. Clin Cancer Res. 2022. PMID: 35980349 Free PMC article. Clinical Trial.
Association of PD-L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR-mutated NSCLC.
Hamakawa Y, Agemi Y, Shiba A, Ikeda T, Higashi Y, Aga M, Miyazaki K, Taniguchi Y, Misumi Y, Nakamura Y, Shimokawa T, Saigusa Y, Kobayashi N, Okamoto H, Kaneko T. Hamakawa Y, et al. Among authors: nakamura y. Cancer Med. 2023 Sep;12(17):17788-17797. doi: 10.1002/cam4.6405. Epub 2023 Aug 7. Cancer Med. 2023. PMID: 37548381 Free PMC article.
Entrectinib Response to ROS1-Fusion-Positive Non-Small-Cell Lung Cancer That Progressed on Crizotinib with Leptomeningeal Metastasis: A Case Report.
Sawada H, Taniguchi Y, Iizuka S, Ikeda T, Aga M, Hamakawa Y, Miyazaki K, Misumi Y, Agemi Y, Nakamura Y, Maeda K, Shimokawa T, Okamoto H. Sawada H, et al. Among authors: nakamura y. Case Rep Oncol. 2023 Dec 12;16(1):1558-1567. doi: 10.1159/000534549. eCollection 2023 Jan-Dec. Case Rep Oncol. 2023. PMID: 38089732 Free PMC article.
Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320).
Otani S, Sasaki J, Nakahara Y, Fukui T, Igawa S, Naoki K, Bessho A, Hosokawa S, Fukamatsu N, Nakamura Y, Kasai T, Sugiyama T, Tokito T, Seki N, Hamada A, Okamoto H, Masuda N. Otani S, et al. Among authors: nakamura y. Invest New Drugs. 2021 Apr;39(2):530-536. doi: 10.1007/s10637-020-01031-z. Epub 2020 Nov 7. Invest New Drugs. 2021. PMID: 33159674 Clinical Trial.
14,270 results
You have reached the last available page of results. Please see the User Guide for more information.